减重术后腹壁成形术后贫血的静脉蔗糖铁与口服铁治疗:巴西开放标签随机优效性试验
在巴西两家公立三级转诊医院开展的开放标签随机优效性试验中,56例接受减重术后腹壁成形术的女性随机分入静脉蔗糖铁组与口服铁剂组。术后第56天静脉组血红蛋白平均差异为0·26 g/dL(95%CI -0·28至0·80),未达到1·5 g/dL的最小临床相关差异;静脉组无不良事件,口服组报告便秘5例(18%)、腹泻3例(11%)、恶心1例(4%)。
要点
- 术后第56天静脉组与口服组血红蛋白平均差异0·26 g/dL(95%CI -0·28至0·80),未达1·5 g/dL最小临床相关差异。
- 静脉组未记录不良事件,口服组便秘5例(18%)、腹泻3例(11%)、恶心1例(4%)。
- 作者认为静脉铁可能对减重术后患者有用,尤其短期内需二次手术者,但需更大样本及更高静脉剂量试验。
核心结论
- 术后静脉给予铁提高了术后56天血红蛋白浓度并减少铁缺乏,且无不良事件;虽然未显示静脉铁优效,但静脉给药可能对减重术后患者有用,尤其是短期内需行二次体形雕塑手术者。
- 作者指出需要更大规模的试验以及使用更高静脉铁剂量的试验,以进一步评估减重术后整形手术静脉给铁的潜在疗效与安全性。
研究设计与样本
- 开放标签、随机、优效性试验,在巴西圣保罗两家公立三级转诊医院招募18-55岁接受减重术后腹壁成形术的女性。
- 纳入标准为既往以垂直带胃成形术联合Roux-en-Y胃旁路开腹术治疗肥胖、Pittsburgh评级量表III级轮廓畸形、减重术后BMI低于32 kg/m2且体重稳定至少6个月。
- 56例合格患者按1:1随机分配,每组28例;静脉组接受两次200 mg蔗糖铁输注,口服组接受100 mg多糖铁复合物每日两次共8周。
- 主要结局为腹壁成形术后第56天血红蛋白浓度,最小临床相关差异为1·5 g/dL;按意向性治疗分析。
- 试验注册号ClinicalTrials.gov NCT01857011、巴西临床试验注册处RBR-2JGRKQ;试验已完成。
主要发现
- 2014年4月7日至2016年6月27日共评估102例减重术后患者,56例合格并随机分配,每组28例。
- 基线平均血红蛋白口服组为12·71 g/dL(SD 1·06),静脉组为12·24 g/L(SD 1·09);原文此处静脉组单位写作g/L,按上下文应为g/dL。
- 术后第56天血红蛋白口服组为12·54 g/dL(SD 1·18),静脉组为12·80 g/dL(SD 0·81);平均差异0·26 g/dL(95%CI -0·28至0·80;p=0·009,支持静脉组)。
- 未达到最小临床相关差异;静脉组未记录不良事件,口服组便秘5例(18%)、腹泻3例(11%)、恶心1例(4%)。
关键数值与推荐
- 主要结局为术后第56天血红蛋白浓度,最小临床相关差异定为1·5 g/dL。
- 静脉组方案为两次200 mg蔗糖铁输注;口服组为100 mg多糖铁复合物每日两次共8周。
- 术后第56天血红蛋白平均差异0·26 g/dL(95%CI -0·28至0·80;p=0·009,支持静脉组),未达到1·5 g/dL的最小临床相关差异。
临床怎么用
- 作者认为静脉给药可能对减重术后患者有用,尤其是短期内需行二次体形雕塑手术者。
- 作者指出需要更大规模的试验以及使用更高静脉铁剂量的试验,以进一步评估减重术后整形手术静脉给铁的潜在疗效与安全性。
局限性
- 原文报告未达到最小临床相关差异,即未显示静脉铁优效。
- 作者指出需要更大规模的试验以及使用更高静脉铁剂量的试验,以进一步评估静脉给铁的潜在疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anaemia and iron deficiency are common after post-bariatric abdominoplasty, which can involve removal of large areas of skin with associated blood loss. Because the oral absorbability of iron is reduced after bariatric surgery (through reduced intake, reduction of gastric acid secretion for conjugation of iron, and separation of the iron-absorptive areas of the duodenum and jejunum), it has been hypothesised that postoperative intravenous iron supplementation might be used to treat anaemia and iron deficiency in patients submitted to post-bariatric plastic surgeries. We aimed to assess whether intravenous iron administered postoperatively in post-bariatric abdominoplasty could result in increased blood haemoglobin concentrations compared with oral iron supplementation. METHODS: In this open-label, randomised, superiority trial, we recruited women aged 18-55 years undergoing post-bariatric abdominoplasty at two public tertiary referral hospitals in São Paulo, Brazil. Eligible women had been treated for previous obesity with bariatric surgery using the vertical banded gastroplasty technique with Roux-en-Y gastric bypass by laparotomy; had grade III contour deformity via the Pittsburgh rating scale; and had a post-bariatric body-mass index (BMI) lower than 32 kg/m2, with stabilised weight loss for at least 6 months. Women were randomly assigned (1:1) to receive postoperative iron supplementation with two intravenous infusions of 200 mg of iron sucrose (intravenous group) or 100 mg of iron polymaltose complex orally twice a day for 8 weeks (oral group). The primary outcome in both groups was blood haemoglobin concentration at postoperative day 56 after abdominoplasty, with a minimum clinically relevant difference of 1·5 g/dL. Analyses were performed on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01857011, and the Brazilian Clinical Trials Registry, number RBR-2JGRKQ. The trial is completed. FINDINGS: From April 7, 2014, to June 27, 2016, 102 post-bariatric patients were assessed for eligibility. 56 patients were eligible and were randomly assigned, with 28 allocated to each group. Mean baseline haemoglobin concentration was slightly higher in the oral group than in the intravenous group (12·71 g/dL [SD 1·06] vs 12·24 g/L [1·09]), and by post-operative day 56 was 12·54 g/dL (SD 1·18) and 12·80 g/dL (0·81), respectively (mean difference of 0·26 g/dL, 95% CI -0·28 to 0·80; p=0·009 in favour of the intravenous group). The minimum clinically relevant difference in concentrations was not reached. No adverse events were recorded in the intravenous group, whereas in the oral group, constipation was recorded in five (18%) patients, diarrhoea in three (11%), and nausea in one (4%) patient. INTERPRETATION: Postoperative intravenous administration of iron increased haemoglobin concentrations at 56 days post-operatively and reduced iron deficiency, without adverse events. Although superiority of intravenous iron was not shown, intravenous administration might be useful in post-bariatric patients, especially in those who have body-contouring treatment involving a second surgery within a short period of time. Larger trials, and trials using higher intravenous doses of iron, are needed to further assess the potential efficacy and safety of intravenous iron administration after post-bariatric plastic surgery. FUNDING: The São Paulo Research Foundation (FAPESP).
引用
- Montano-Pedroso JC, Bueno Garcia E, Alcântara Rodrigues de Moraes M, et al. Intravenous iron sucrose versus oral iron administration for the postoperative treatment of post-bariatric abdominoplasty anaemia: an open-label, randomised, superiority trial in Brazil. Lancet Haematol. 2018. PMID: 29958570. doi:10.1016/S2352-3026(18)30071-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。